Comissão científica
Colaboradores
The SOC1 study discusses whether or not to adopt a secondary cytoreductive surgery associated with a new cycle of chemotherapy in women with ovarian cancer. Conducted in China, it selected patients with the first recurrence of ovarian cancer who were sensitive to platinum. This is a multicenter, open, randomized, phase III study, carried out in four academic centers with high experience in oncologic surgery for ovarian cancer. “In addition to being platinum-sensitive, women over 18 years of age with relapsed ovarian cancer needed to have potentially resectable disease according to the international model score (iMODEL) and PET-CT images,” explains Glauco Costa Silveira, clinical oncologist at the Oncoclínicas Group in Uberlândia (MG).
Secondary cytoreduction followed by chemotherapy was associated with significantly longer progression-free survival than chemotherapy alone in patients with relapsing platinum-sensitive ovarian cancer. The authors state that patients should be advised about the option of secondary cytoreduction in specialized centers.
“Ovarian cancer does not have an efficient screening protocol. For 2021, between 6,500 and 7,000 new cases are expected in Brazil, with a mortality of approximately 4,500 women. Both early diagnosis and therapies for cases of recurrence are challenges that we still have to overcome”, points out clinical oncologist Elge Werneck, from the Curitiba Institute of Hematology (IHOC), from the Oncoclínicas Group, which reinforces the importance of works such as This one.
Access our website and read the full article with all the details of this study.
